Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research

CHICAGO, Oct. 20, 2011 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for INTC, MOS, DECK, FL, and JAZZ.

To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/102011A (Note: You may have to copy this link into your browser then press the [ENTER] key.)

Today's PriceWatch Alerts cover the following stocks: Intel Corporation (Nasdaq: INTC), Mosaic Co. (NYSE: MOS), Deckers Outdoor Corp. (Nasdaq: DECK), Foot Locker, Inc. (NYSE: FL), and Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ).

In today's unsure markets these brief PriceWatch Alerts contain concise detailed strategies for each covered stock and include position protection tactics designed to potentially defend investors from unexpected market shifts. While other market reports only provide stock news and opinion, we offer strategies that position investments against uncertainty and increase chances of making a profit, even if a stock goes down.

"Our PriceWatch Alerts go beyond other market reports. Along with a brief concise overview, each PriceWatch Alert provides useful strategies, which ensure potential investments are protected with basic hedging techniques," says Reid Stratton, Seven Summits Senior Analyst. "These brief company reports contain information that can benefit expert and novice investors who want to stay ahead of the market."  

For essential information on stocks poised to move go to:

http://www.iotogo.com/s/102011A for Seven Summits Strategic Investments' PriceWatch Alerts.

Seven Summits Investment Research is an independent investment research group, which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help our clients make the best possible investment decisions. For more information go to www.SevenSummitsInvestmentResearch.com . CRD# 137114

All stocks and options shown are examples only-- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security.  Potential returns do not take into account your trade size, brokerage commissions or taxes--expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available from Catherine at 800-698-9101 or at http://www.cboe.com/Resources/Intro.aspx . Privacy policy available upon request.

SOURCE Seven Summits Investment Research

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”